Hormonal
Tirzepatide (5-15 mg once weekly) significantly reduces the risk of composite kidney endpoints (eGFR decline ≥40%, renal death, kidney failure, or new-onset macroalbuminuria) in patients with type 2 diabetes and high cardiovascular risk compared to insulin glargine.
If you have type 2 diabetes and are at high risk for heart or kidney problems, tirzepatide (a once-weekly injection) has been shown to significantly reduce the risk of serious kidney issues compared to insulin glargine. This benefit includes slowing the decline in kidney function and preventing the onset of severe protein in the urine. While there may be an initial, reversible drop in kidney function numbers, this is a sign of reduced stress on the kidneys. Always consult your doctor to see if this treatment is appropriate for your specific health profile.
Tirzepatide participants presented significantly fewer composite kidney endpoints (eGFR decline ≥40% from baseline, renal death, kidney failure or new-onset macroalbuminuria, i.e. UACR >300 mg/g, A3) [HR 0.59 (95% CI 0.43–0.80); P < .05]
Why this rating
Based on a post hoc analysis of a large, randomized clinical trial (SURPASS-4) with a median follow-up of 85-104 weeks.
Source
Tirzepatide and prevention of chronic kidney disease
Catalina Bosch et al. · Clinical Kidney Journal · 2022
DOI 10.1093/ckj/sfac274
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →